Sign up to save your podcasts
Or
Share Eli Lilly and Company (LLY), 2024 Q4 earnings digest
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Eli Lilly and Company (LLY), 2024 Q4 earnings digest
$LLY has just released its Q4 2024 earnings report, highlighting robust revenue growth of 45% compared to Q4 2023, driven by strong performance from Mounjaro and Zepbound. Key risks include the competitive landscape in the incretin market and ongoing pricing pressures.
View all episodes
By ValueVerge$LLY has just released its Q4 2024 earnings report, highlighting robust revenue growth of 45% compared to Q4 2023, driven by strong performance from Mounjaro and Zepbound. Key risks include the competitive landscape in the incretin market and ongoing pricing pressures.